EXPEDITION
LIVE

Serial Number

98978174

Owner

Flagship Labs 94, Inc.

Attorney

Christina M. Licursi

First Use Date

May 26, 2025

Filing Date

Oct 4, 2024

Add to watchlist:

No watchlists yet
View on USPTO

EXPEDITION Trademark

Serial Number: 98978174

EXPEDITION is a trademark filed by Flagship Labs 94, Inc. on October 4, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Flagship Labs 94, Inc. (3 trademarks)

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

EXPEDITION MEDICINES, INC. (7 trademarks)

55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142

Entity Type: 03

Trademark Details

Filing Date

October 4, 2024

Registration Date

Not Registered

First Use Anywhere

May 26, 2025

First Use in Commerce

May 26, 2025

Published for Opposition

September 16, 2025

Goods & Services

Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders

Scientific research, namely, research and analysis services for the design and characterization of chemical therapeutic products; research services in the fields of proteomic analysis; proteomic analysis for scientific and research purposes; medical and scientific research in the field of proteomics; research and development in the field of proteomics; medical research, namely, compiling data for research purposes in the field of proteomics

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 27, 2026 EXRA
STATEMENT OF USE PROCESSING COMPLETE
May 26, 2026 SUPC
SOU EXTENSION 2 GRANTED
May 26, 2026 EX2G
DIVISIONAL PROCESSING COMPLETE
May 26, 2026 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 2, 2026 AITU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2025 EXRA
USE AMENDMENT FILED
Dec 11, 2025 IUAF
DIVISIONAL REQUEST RECEIVED
Dec 11, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Dec 11, 2025 ERTD
TEAS STATEMENT OF USE RECEIVED
Dec 11, 2025 EISU
SOU EXTENSION 1 GRANTED
Dec 11, 2025 EX1G
SOU EXTENSION 1 FILED
Dec 11, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 11, 2025 EEXT
SOU EXTENSION 2 FILED
Dec 10, 2025 EXT2
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 16, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 16, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 10, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 14, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 31, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 31, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 31, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 1, 2025 GNRN
NON-FINAL ACTION E-MAILED
May 1, 2025 GNRT
NON-FINAL ACTION WRITTEN
May 1, 2025 CNRT
ASSIGNED TO EXAMINER
Apr 9, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 3, 2025 NWOS
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 5, 2025 ASGN
NEW APPLICATION ENTERED
Oct 4, 2024 NWAP